Publications
Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017. PMID: 29182496
Jones ME, Schoemaker MJ, Wright LB, Ashworth A, Swerdlow AJ. Smoking and risk of breast cancer in the Generations Study cohort. Breast cancer research : BCR. 2017. PMID: 29162146
Singh KP, Dhruva AA, Flowers E, Kober KM, Miaskowski C. A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting. Critical reviews in oncology/hematology. 2017. PMID: 29279099
Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang YH, Shen YS, Olivas V, Jami KM, Moroz A, Jego B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang CI, Evans MJ. Imaging PD-L1 Expression with ImmunoPET. Bioconjugate chemistry. 2017. PMID: 29125731
Ursem C, Venook AP. The Developing Role of Anti-Epidermal Growth Factor Receptor Agents in the Treatment of Advanced or Metastatic Colorectal Cancer. Oncology (Williston Park, N.Y.). 2017. PMID: 29179247
Lindquist KJ, Sanford T, Friedlander TW, Paris PL, Porten SP. Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors. PloS one. 2017. PMID: 29140994
Terranova-Barberio M, Thomas S, Munster PN. Host histone acetylation unlocks HDAC inhibitor potential. Oncotarget. 2017. PMID: 29290932
Aggarwal R. Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers. European urology. 2017. PMID: 29128209
Brice Tiret, Adam Autry, Ilwoo Park, Ming Lu, Rana Anjum, Liza Drew, Sebastien Degorce, Michele Mayo, Keith Dillman, James Rubenstein, Myriam M Chaumeil. EXTH-71. HYPERPOLARIZED [1-13C] PYRUVATE AS A BIOMARKER FOR TREATMENT MONITORING IN LYMPHOMA MURINE MODELS. Neuro-oncology. 2017. PMID:
Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nature genetics. 2017. PMID: 29106415
Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, Rangwala R, Varga A. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017. PMID: 29095678
Algazi AP, Esteve-Puig R, Nosrati A, Hinds B, Hobbs-Muthukumar A, Nandoskar P, Ortiz-Urda S, Chapman PB, Daud A. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. Pigment cell & melanoma research. 2017. PMID: 28921907
Kerkhoff AD, Patrick L, Cornett P, Kleinhenz ME, Brondfield S. Severe piperacillin-tazobactam-induced hemolysis in a cystic fibrosis patient. Clinical case reports. 2017. PMID: 29225856
Ko AH. Clinical Management: Metastatic Disease. Volume 23 of Issue 6 Cancer journal (Sudbury, Mass.). 2017. PMID: 29189332
Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J. Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast cancer research and treatment. 2017. PMID: 28884461
Lancman G, Tremblay D, Barley K, Barlogie B, Cho HJ, Jagannath S, Madduri D, Moshier E, Parekh S, Chari A. The effect of novel therapies in high-molecular-risk multiple myeloma. Clinical advances in hematology & oncology : H&O. 2017. PMID: 29200420
Rugo HS. Real-world use of scalp cooling to reduce chemotherapy-related hair loss. Clinical advances in hematology & oncology : H&O. 2017. PMID: 29200414
Gangadhar TC, Hwu WJ, Postow MA, Hamid O, Daud A, Dronca R, Joseph R, O'Day SJ, Hodi FS, Pavlick AC, Kluger H, Oxborough RP, Yang A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS. Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. Journal of immunotherapy (Hagerstown, Md. : 1997). 2017. PMID: 29028788
Tempero MA. Introduction: Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. Cancer journal (Sudbury, Mass.). 2017. PMID: 29189324
Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. European journal of cancer (Oxford, England : 1990). 2017. PMID: 28961465